z-logo
Premium
Role of the fibroblast growth factor receptor axis in cholangiocarcinoma
Author(s) -
Ang Celina
Publication year - 2015
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12916
Subject(s) - medicine , fibroblast growth factor receptor , fibroblast growth factor , cancer research , fibroblast growth factor receptor 2 , receptor , fibroblast growth factor receptor 3 , oncology
Advanced cholangiocarcinoma ( CCA ) is a highly lethal disease with limited therapeutic options beyond cytotoxic chemotherapy. Molecular profiling of CCA has provided insights into the pathogenesis of this disease and identified potential therapeutic targets. The fibroblast growth factor receptor ( FGFR ) axis is important for maintaining tissue homeostasis. Aberrations in FGFR activity have been implicated in the development and progression of CCA and other malignancies, which has generated significant interest in exploring FGFR 's therapeutic potential. FGFR2 fusion events are present in up to 17% of intrahepatic CCAs and appear to predict sensitivity to FGFR inhibitors even after progression on chemotherapy. These observations have led to a clinical trial evaluating FGFR inhibition in patients with CCA enriched for FGFR alterations. This review summarizes current knowledge about the role of the FGFR pathway in cholangiocarcinogenesis and ongoing work in developing FGFR ‐directed therapies as an antineoplastic strategy for CCA .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here